CNGB3 and achromatopsia: Thus, 2 phase I/II clinical trials [NCT02599922] to evaluate the safety and efficacy of gene therapy for achromatopsia in patients with a mutation in the cyclic nucleotide gated channel gene (CNG)-B3 have been registered, one of which has been completed [NCT03001310].